888vipbet

888vipbet Giants release Daniel Jones: What it means for N.Y. and what comes next for the QBSen. Mitch McConnell said Thursday he will lead a subcommittee overseeing defense spending as he carves out new roles once he relinquishes his long-running post as Senate Republican leader. The Kentucky Republican revealed he will assume the chairmanship of the Senate Appropriations Subcommittee on Defense. The role dovetails with his constant message that America needs a bulked-up military to deter threats from adversaries such as Russia, Iran and China. The transition comes as McConnell is ending his role as the longest-serving Senate leader in history, just as Republicans prepare to take majority control of the chamber after big gains in this month's election. Republicans elected South Dakota Sen. John Thune , a top deputy to McConnell, as the next Senate majority leader. McConnell, 82, said Thursday he will assume the subcommittee chairmanship at a critical time. “America’s national security interests face the gravest array of threats since the Second World War," the senator said in a statement. “At this critical moment, a new Senate Republican majority has a responsibility to secure the future of U.S. leadership and primacy.” McConnell frequently evokes Ronald Reagan’s mantra of “peace through strength” when discussing foreign policy risks and how the U.S. should respond. McConnell's stance could clash with President-elect Donald Trump’s “America First” doctrine on foreign affairs. McConnell worked with Trump on a tax cuts package and the appointment of conservative judges — including three justices to the nine-member Supreme Court — during Trump's first term as president. Fighting back against isolationism within his own party, McConnell has championed sending weapons and other aid to Ukraine as it fends off Russia’s invasion. McConnell said Thursday he's also set to become chairman of the Senate Rules Committee, which is often a more low-key panel at the center of big issues, both at the Capitol and in the country. The committee oversees the administration of the Senate side of the building, including during inaugurations. But it also puts McConnnell at the center of weighty topics, namely federal elections and voting rights as well as the procedures of the Senate, including the debate around the filibuster. McConnell said the committee will have important work in the coming two years. “Defending the Senate as an institution and protecting the right to political speech in our elections remain among my longest-standing priorities,” he said. There had been considerable speculation about what roles McConnell would take after stepping down as Republican leader. He has two years left in his current Senate term and has not signaled whether he will run for reelection in Kentucky in 2026. McConnell has been a prolific appropriator for the Bluegrass State, a role he’s well positioned to continue.Mikaela Shiffrin suffers abrasion on hip during crash on final run of World Cup giant slalom

Pakistan's missile program is 'emerging threat', top US official saysLopsided loss sinks the reeling Saints further into evaluation mode

Wellesley’S Andrew Young Launches Personal Blog To Share Insights And Innovations In BiotechnologyMissing Hawaii woman Hannah Kobayashi's last known movements as her family take search into their own hands

Overhaul brings new life to N.M.'s once-troubled veterans homeTwo senior members of the federal cabinet were in Florida Friday pushing Canada’s new border plan with Donald Trump’s transition team, a day after Trudeau himself appeared to finally push back at the president-elect over his social media posts about turning Canada into the 51st state. Both Trudeau and former Bank of Canada governor Mark Carney, who Trudeau has been courting to become Canada’s next finance minister, shared posts on X Thursday, a day after Trump’s latest jab at Canada in his Christmas Day message. It isn’t clear if Finance Minister Dominic LeBlanc, who has repeatedly insisted Trump’s 51st state references are a joke, will raise the issue with Trump’s team when he and Foreign Affairs Minister Mélanie Joly meet with them in Palm Beach. The two are there to discuss Canada’s new $1.3 billion border plan with just under four weeks left before Trump is sworn in again as president. He has threatened to impose a new 25 per cent import tariff on Canada and Mexico the same day over concerns about a trade imbalance, as well as illegal drugs and migration issues at the borders. The broad strokes of Canada’s plan were made public Dec. 17, including a new aerial intelligence task force to provide round-the-clock surveillance of the border, and improved efforts using technology and canine teams to seek out drugs in shipments leaving Canada LeBlanc’s spokesman, Jean-Sébastien Comeau, said the ministers will also emphasize the negative impacts of Trump’s threatened tariffs on both Canada and the U.S. Comeau said the ministers will build on the discussions that took place last month when Trudeau and LeBlanc met Trump at Mar-a-Lago just days after Trump first made his tariff threat. It was at that dinner on Nov. 29 when Trump first raised the notion of Canada becoming the 51st state, a comment LeBlanc has repeatedly since insisted was just a joke. But Trump has continued the quip repeatedly in various social media posts, including in his Christmas Day message when he said Canadians would pay lower taxes and have better military protection if they became Americans. He has taken to calling Trudeau “governor” instead of prime minister. Trudeau had not directly responded to any of the jabs, but on Thursday posted a link to a six-minute long video on YouTube from 2010 in which American journalist Tom Brokaw “explains Canada to Americans.” The video, which originally aired during the 2010 Vancouver Olympics, explains similarities between the two countries, including their founding based on immigration, their trading relationship and the actions of the Canadian Army in World War 2 and other modern conflicts. “In the long history of sovereign neighbours there has never been a relationship as close, productive and peaceful as the U.S. and Canada,” Brokaw says in the video. Trudeau did not expand about why he posted a link to the video, posting it only with the words “some information about Canada for Americans.” Carney, who is at the centre of some of Trudeau’s recent domestic political troubles, also called out Trump’s antics on X Thursday, calling it “casual disrespect” and “carrying the ‘joke’ too far.” “Time to call it out, stand up for Canada, and build a true North American partnership,” said Carney, who Trudeau was courting to join his cabinet before Chrystia Freeland resigned as finance minister last week. Freeland’s sudden departure, three days after Trudeau informed her he would be firing her as finance minister in favour of Carney, left Trudeau’s leadership even more bruised than it already was. Despite the expectation Carney would assume the role, he did not and has not made any statements about it. LeBlanc was sworn in as finance minister instead the same day Freeland quit. More than two dozen Liberal MPs have publicly called on Trudeau to resign as leader, and Trudeau is said to be taking the holidays to think about his next steps. He is currently vacationing in British Columbia.

Trump 2.0: A Global Agent Of Change?Vasko's 4 TDs power Coastal Carolina past Georgia State 48-27 to become bowl eligibleVancouver Canucks fans are a pretty wise bunch and they’ve been through the ringer more than once. In 2024, they witnessed the return of playoff hockey. That was a high point. But they also witnessed their team stumble its way through the first half of the 2024-25 season. “I’m not content at all but there’s been a lot thrown to this team, let’s face it,” head coach Rick Tocchet said Friday. “People in and out, stuff like that, lot of noise. To be where we’re at is a positive. Like Quinn (Hughes) said the other day, we know we have some guys that we need to play better, but to be in our situation, that’s a positive.” And now the team is without Hughes and Elias Pettersson , both dealing with undisclosed injuries suffered in recent games, for at least Saturday’s game. The team is still in a playoff spot, but it’s a tenuous situation. So what are the resolutions Canucks fans are making this season? I am going to appreciate every second Quinn Hughes is on the ice. It’s going to be a short time in Canucks history that “we” have a player that great. — Shane Austin via BlueSky We are going to be reminded just how big a load Hughes carries for this team when he misses Saturday’s game with his undisclosed injury, apparently suffered last Saturday versus Ottawa. There’s just no filling the hole left by him. He’s the most thrilling and dynamic skater this city has seen, certainly since Pavel Bure. The Canucks control the game when he’s on the ice; they chase it when he’s on the bench. We’re likely to see ugly hockey for as long as he’s out. Much like Andy Bernard, who said “I wish there was a way to know you’re in the good old days before you’ve actually left them.” I resolve not to take for granted all of the successes the team currently have in the quest for the Cup. Too many dark years to not appreciate what we have now. — Derek Kwan via BlueSky This is a long-winded version of the answer every veteran athlete gives when they’re asked about what the advice they give to athletes getting sent to enter the big stage for the first time: just enjoy it. What they always mean is that the first time is when everything looks rich and pure, with no nonsense. The world seems all yours. It’s a moment you will never feel again. So try to hold on to that spirit as best you can. It’s good advice for fans, too. To be grateful that we are beyond the darkness (Jim Benning and COVID eras) and to enjoy the sporting thrills (like a roller-coaster, for there to be highs, there must be lows) no matter the result. — The Tao of Oat on BlueSky This is a lovely follow-on to the point made above. Hot take: Most talented Canuck roster all time. May they find a way to put it all together. — Aaron via BlueKsy This is bold. And I’m sorry Aaron, I just don’t think you can look at this D corps, even with the best defenceman in team history, and say it’s better than the 2011 defence corps. The forwards are good and pretty deep, but again, the 2011 forwards had the Sedins and two of the best two-way forwards in team history in Alex Burrows and Ryan Kesler in their primes. I admire the optimism, but I’m not buying it. I hope they finally find a D man that can exercise the ghost that Quinn Hughes keeps seeing. — Myra C. via BlueSky Even before Hughes suffered whatever injury he’s dealing with this week, before Filip Hronek hurt his shoulder last month, Canucks management was on the hunt for another defencemen. It’s no secret they want to add a blue-liner who is adept at moving the puck. That’s been clearly the case since the summer. This is a big, bruising group that, outside of Hughes and Hronek and, when he’s on his game, Erik Brännström, doesn’t have a whole of puck-moving talent. As for the ghost face, that’s just how the man focuses. Let’s hope we get to see it again soon. pjohnston@postmedia.comSRF: What does the group of 100-year-olds in Switzerland look like? Daniela Jopp: There are 2,086 centenarians in Switzerland. Of these, 80% are women. Almost half of them live in care facilities, the other half live in private households. That’s quite astonishing, because 80 years ago there were only a handful of 100-year-olds. SRF: How are 100-year-olds doing in Switzerland? DJ: A look at well-being reveals an astonishing finding: in Switzerland, 92% of centenarians say they are satisfied with their lives. This is a remarkable result that has also been observed in previous studies in other countries, but never to such a high degree. It seems that Swiss centenarians are particularly satisfied with their lives. SRF: What factors explain this satisfaction? DJ: Objective health does not play a central role. Although centenarians have an average of six physical limitations and often also cognitive impairments, these factors have little influence on satisfaction. What’s far more important are psychological aspects, such as the feeling of not being lonely. So-called psychological strengths are particularly decisive: a belief in one’s own control over life, optimism, a positive view of the future, a sense of meaning in life, and a strong will to live. These elements are the most important drivers of well-being in old age. SRF: What kind of personalities are these centenarians in Switzerland? DJ: We know that certain personality traits, such as extroversion, that is, whether you like approaching people, or a positive basic attitude, play a role and are partly genetically determined. We also see that many of the Swiss centenarians have not had an easy life. A third have lost at least one child, one of the most difficult life events. It is a combination of a genetic predisposition for optimism and dealing with crises that helps them to remain exceptionally resilient and thus probably live longer. SRF: How important are genetics? DJ: Numerous studies have investigated this and show that it is not primarily our genes but our lifestyle that is decisive for our lifespan. Genetics only play a role of around 25%. The larger proportion of 70% to 80% depends on a healthy diet, exercise, mental fitness and social relationships, as well as a positive attitude to life and a sense of purpose. SRF: What role do personal interests and hobbies play? DJ: An exciting observation from my studies on centenarians is that many of them pursue a deep passion. Whether it’s a close bond with their family, for example, by actively supporting their grandchildren, or a strong interest in politics, art or other areas of life – this dedication seems to inspire them. I think we can learn from the centenarians how important it is to realise at a younger age what really inspires and drives us. It is precisely these passions that not only give us purpose and energy, but often carry us into old age. Translated from German using DeepL/amva/gw

Johnson Lukaza Unveils Brand New Personal Website To Inspire Innovation And Leadership

( MENAFN - IANS) United Nations, Dec 28 (IANS) UN Secretary-General Antonio Guterres is saddened by the passing of India's former Prime Minister Manmohan Singh, who played a "pivotal role" in shaping the nation's "economic trajectory", according to his Associate Spokesperson Stephanie Tremblay. "The Secretary-General was saddened to learn of the passing of Dr Manmohan Singh," she said in a statement on Friday. He "played a pivotal role in India's recent history, particularly in shaping its economic trajectory," the statement said. "As Prime Minister from 2004 to 2014, Singh oversaw a period of significant economic growth and development in India." "Under his leadership, India also strengthened its collaboration with the United Nations, contributing actively to global initiatives and partnerships," it added. Singh cooperated with Guterres's two predecessors Kofi Annan and Ban Ki-moon during his 10 years as Prime Minister, meeting them at the UN headquarters in New York as well as at other international forums. Singh addressed the UN General Assembly five times. Fighting climate change has been a top item in the UN's agenda along with sustainable development for poverty eradication. In pursuing these goals, Singh reiterated India's commitment but also constantly reminded world leaders that the developing countries' historical context should be taken into account and the developed countries had a special responsibility in pursuing them. At the UN Climate Change Conference in Denmark in 2009, he declared, "India was a latecomer to industrialisation and as such we have contributed very little to the accumulation of greenhouse gas emissions that caused global warming, but we are determined to be part of the solution." When the negotiations began while he was Prime Minister for the landmark Paris Climate Change Accord that was adopted in 2015, he made it a firm condition that it should be "equitable" taking into account the disproportionate role the developed countries had in creating the greenhouse gas crisis and its consequences suffered by developing countries. He also attended the Rio+, the UN Conference on Sustainable Development in Rio De Janeiro in 2012. While criticising the developed countries for their parsimony in funding development around the world, he also said, "Sustainable development mandates the efficient use of available natural resources. We have to be much more frugal in the way we use natural resources." While the UN was working on its ambitious 2030 Sustainable Development Goals that was adopted in 2015 after he left office, Singh emphasised that it should provide funding for developing countries and technology transfer. In 2013 in his last address to the UN General Assembly, he said, "The problems of over a billion people living in abject poverty around the world need to be attacked more directly. Poverty remains a major political and economic challenge and its eradication requires special attention and a new collective thrust." "It is, therefore, important that the UN set clear and concise goals (for its sustainable development agenda) and provide practical and well-defined means of implementation, including the adequate flow of resources and transfer of technology, taking the views of developing countries fully into account," he added. MENAFN27122024000231011071ID1109036087 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.( MENAFN - PR Newswire) Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI ) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million, before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon, PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen, CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." "HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China," said Dr. Robert Y. Zhao, President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million, Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan, has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024. Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024. Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein, MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20th at 8:00 AM EST (5:00 AM PST) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio. To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at , as well as on the Investor and News section of Aadi's website at . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024, and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: [email protected] SOURCE Aadi Bioscience MENAFN19122024003732001241ID1109014329 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Predictive Safety Announces Partnership with DISA Global SolutionsRavens WR Zay Flowers (shoulder) questionable vs. Texans

NoneKane hat-trick sends Bayern eight points clearKILLINGTON, Vt. (AP) — American skier Mikaela Shiffrin said she suffered an abrasion on her left hip and that something “stabbed” her when she crashed during her second run of a World Cup giant slalom race Saturday, doing a flip and sliding into the protective fencing. Shiffrin stayed down on the edge of the course for quite some time as the ski patrol attended to her. She was taken off the hill on a sled and waved to the cheering crowd before going to a clinic for evaluation. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week

New Delhi, December 22: Google does not agree with the decision of the Department of Justice (DOJ) lawsuit on how search engines are distributed. The company plans to appeal to the decision of the DOJ search distribution lawsuit. The DOJ's proposal suggests significant changes, including the potential sale of Google Chrome and restrictions on agreements with partners. In response, Google has offered its own remedies proposal. Google stated, "DOJ filed a proposal reflecting an interventionist agenda. Its proposal goes far beyond what the Court’s decision is actually about our agreements with partners to distribute search." Google is putting together a proposal for remedies as the legal process requires both sides to explain what solutions they think would be appropriate in response to the court's ruling, which is scheduled for April 2025. Google Releases Android 16 2nd Developer Preview Update; Check Details. The tech giant said, "People don't use Google because they have to, they use it because they want to." The DOJ believed that Google's investments in Chrome, the development of AI, the way Google searches the web, or how it creates algorithms could be seen as unfair competition. However, the DOJ did not choose to pursue those cases. Google pointed out that the DOJ's proposal would negatively impact American consumers and weaken the US position as a leader in global technology at a crucial time. It would force Google to share users' private search queries with foreign and domestic competitors, and it would limit their ability to innovate and improve their products. Google has submitted its proposal, which is based on the actual findings from the court's decision regarding its search distribution contracts. The proposal aims to ensure that web browsers can continue to provide Google Search to their users and also earn revenue from that partnership. Google Search Console To Get ‘24 Hours’ View With Hourly Data for Performance Report Soon. Additionally, Google's proposal offers flexibility for browsers. It would allow them to have different default search engines for various platforms, such as using a different search engine for iPhones and iPads. It would enable users to change their default search provider at least once a year. (The above story first appeared on LatestLY on Dec 22, 2024 07:13 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com ).

Attacks such as Magdeburg strike at everyone’s securityTroy scores 21 points in less than 2 minutes in the fourth quarter to beat Southern Miss 52-20Minnesota looks to stop skid vs. Bethune-Cookman

Quantummind Breakthrough: Bridging Artificial And Natural IntelligenceAmericans more hopeful about 2025 than they were for 2024 — CBS News pollMcConnell to head subcommittee overseeing defense spending as he prepares to step down as GOP leader